Arthur F. Ryan Sells 100 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Director Arthur F. Ryan sold 100 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, July 1st. The stock was sold at an average price of $1,059.24, for a total value of $105,924.00. Following the sale, the director now directly owns 17,882 shares of the company’s stock, valued at approximately $18,941,329.68. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Regeneron Pharmaceuticals Stock Performance

NASDAQ:REGN opened at $1,024.09 on Thursday. The stock has a market cap of $112.84 billion, a P/E ratio of 30.25, a price-to-earnings-growth ratio of 2.16 and a beta of 0.13. The company has a current ratio of 5.27, a quick ratio of 4.51 and a debt-to-equity ratio of 0.10. The stock’s 50-day moving average is $990.15 and its 200-day moving average is $954.11. Regeneron Pharmaceuticals, Inc. has a 1-year low of $688.52 and a 1-year high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 earnings per share for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion for the quarter, compared to the consensus estimate of $3.19 billion. Regeneron Pharmaceuticals had a return on equity of 16.83% and a net margin of 29.45%. Equities research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have recently weighed in on REGN. Cantor Fitzgerald reissued a “neutral” rating and set a $925.00 target price on shares of Regeneron Pharmaceuticals in a report on Friday, May 3rd. UBS Group raised their price target on Regeneron Pharmaceuticals from $1,090.00 to $1,099.00 and gave the stock a “buy” rating in a research report on Wednesday, April 17th. StockNews.com cut Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 30th. Truist Financial restated a “buy” rating and issued a $1,135.00 price target on shares of Regeneron Pharmaceuticals in a research report on Wednesday, April 3rd. Finally, Morgan Stanley raised their price target on Regeneron Pharmaceuticals from $1,104.00 to $1,115.00 and gave the stock an “overweight” rating in a research report on Wednesday, March 13th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Regeneron Pharmaceuticals presently has an average rating of “Moderate Buy” and an average target price of $1,027.55.

Institutional Trading of Regeneron Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in the company. West Paces Advisors Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 575.0% in the first quarter. West Paces Advisors Inc. now owns 27 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 23 shares during the period. Crewe Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the first quarter worth approximately $28,000. Fortitude Family Office LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $31,000. MCF Advisors LLC lifted its stake in shares of Regeneron Pharmaceuticals by 50.0% in the fourth quarter. MCF Advisors LLC now owns 36 shares of the biopharmaceutical company’s stock worth $32,000 after acquiring an additional 12 shares during the period. Finally, Criterion Capital Advisors LLC acquired a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth approximately $37,000. 83.31% of the stock is currently owned by institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.